Changes in metabolic parameters in patients with severe mental illness over a 10-year period: A retrospective cohort study

Australian and New Zealand Journal of Psychiatry

Volumn 51, Issue 1, 2017, Pages 75-82

  Heald, Adrian H ^a,b   Martin, Julie L ^c   Payton, Tony ^a   Khalid, Luma ^a   Anderson, Simon G ^a,d   Narayanan, R Prakash ^a   De Hert, Marc ^e   Yung, Alison ^f   Livingston, Mark ^g  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b LEIGHTON HOSPITAL   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

^g MANOR HOSPITAL   (United Kingdom)

Author keywords

body mass index; diabetes; glucose; primary care; Severe enduring mental illness

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEUROLEPTIC AGENT; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRIACYLGLYCEROL; TRICYCLIC ANTIDEPRESSANT AGENT; GLUCOSE BLOOD LEVEL;

ADULT; AGE; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DEPRESSION; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG USE; FEMALE; FOLLOW UP; GENDER; GENERAL PRACTICE; GLUCOSE BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; REGISTER; RETROSPECTIVE STUDY; RISK ASSESSMENT; SMOKING; SYSTOLIC BLOOD PRESSURE; UNITED KINGDOM; AGED; BLOOD; METABOLISM; MIDDLE AGED;

AGED; BLOOD GLUCOSE; BODY MASS INDEX; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; REGISTRIES; RETROSPECTIVE STUDIES;

EID: 85008642315     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1177/0004867415625817     Document Type: Article

References (41)

1. Allison DB, Fontaine KR, Moonseong H, et al. (1999a) The distribution of body mass index among Individuals with and without Schizophrenia. Journal of Clinical Psychiatry 60: 215-220.
2. Allison DB, Mentore JL, Heo M, et al. (1999b) Antipsychotic-induced weight gain: A comprehensive research synthesis. American Journal of Psychiatry 156: 1686-1696.
3. Allison DB, Loebel AD, Lombardo I, et al. (2009) Understanding the relationship between baseline BMI and subsequent weight change in antipsychotic trials: Effect modification or regression to the mean? Psychiatry Research 170: 172-176.
4. American Diabetes Association; American Psychiatric Association, American Association of Clinical Endocrinologists and North American Association for the Study of Obesity (2004) Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27: 596-601.
5. Barnett AH, Mackin P, Chaudhry I, et al. (2007) Minimising metabolic and cardiovascular risk in schizophrenia: Diabetes, obesity and dyslipidaemia. Journal of Psychopharmacology 21: 357-373.
6. Berken GH, Weinstein DO, Stern WC, (1984) Weight gain: A side-effect of tricyclic antidepressants. Journal of Affective Disorders 7: 133-138.
7. Bressington DT, Mui J, Cheung EF, et al. (2013) The prevalence of metabolic syndrome amongst patients with severe mental illness in the community in Hong Kong-a cross sectional study. BMC Psychiatry 13: 87.
8. Brown AD, Barton DA, Lambert GW, (2009) Cardiovascular abnormalities in patients with major depressive disorder: Autonomic mechanisms and implications for treatment. CNS Drugs 23: 583-602.
9. Brown S, (1997) Excess mortality of schizophrenia: A meta-analysis. British Journal of Psychiatry 171: 502-508.
10. Cassidy F, Ahearn E, Carroll BJ, (1999) Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. American Journal of Psychiatry 156: 1417-1420.
11. Cohen D, Huinink S, (2007) Atypical antipsychotic-induced diabetes mellitus in child and adolescent psychiatry. CNS Drugs 21: 1035-1038.
12. Correll CU, Frederickson AM, Kane JM, et al. (2008) Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. Bipolar Disorders 10: 788-797.
13. Crump C, Winkleby MA, Sundquist K, et al. (2013) Comorbidities and mortality in persons with schizophrenia: A Swedish national cohort study. American Journal of Psychiatry 170: 324-333.
14. Danaei G, Finucane MM, Lu Y, et al. (2011) Global burden of metabolic risk factors of Chronic Diseases Collaborating Group (Blood Glucose). National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: Systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants. The Lancet 378: 31-40.
15. Daumit GL, Dickerson FB, Wang NY, et al. (2013) Behavioural weight-loss intervention in persons with serious mental illness. New England Journal of Medicine 368: 1594-1602.
16. Daumit GL, Goff DC, Meyer JM, et al. (2008) Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophrenia Research 105: 175-187.
17. Davé S, Petersen I, (2009) Creating medical and drug code lists to identify cases in primary care databases. Pharmacoepidemiology and Drug Safety 18: 704-707.
18. De Hert M, Cohen D, Bobes J, et al. (2011a) Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry 10: 138-151.
19. De Hert M, Correll CU, Bobes J, et al. (2011b) Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 10: 52-77.
20. De Hert M, Dekker JM, Wood D, et al. (2009) Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). European Psychiatry 24: 412-424.
21. Gardner-Sood P, Lally J, Smith S, et al. (2015) Cardiovascular risk factors and metabolic syndrome in people with established psychotic illnesses: Baseline data from the IMPaCT randomized controlled trial. Psychological Medicine 45: 2619-2629.
22. Holt RI, Abdelrahman T, Hirsch M, et al. (2010) The prevalence of undiagnosed metabolic abnormalities in people with serious mental illness. Journal of Psychopharmacology 24: 867-873.
23. Holt RI, Peveler RC, (2009) Obesity, serious mental illness and antipsychotic drugs. Diabetes, Obesity and Metabolism 11: 665-679.
24. Kivimäki M, Lawlor DA, Singh-Manoux A, et al. (2009) Common mental disorder and obesity: Insight from four repeat measures over 19 years: Prospective Whitehall II cohort study. British Medical Journal 339: b3765.
25. McCreadie RG, Kelly C, Connolly M, et al. (2005) Dietary improvement in people with schizophrenia: Randomised controlled trial. British Journal of Psychiatry 187: 346-351.
26. McLean G, Martin JL, Martin DJ, et al. (2014) Standard cardiovascular disease risk algorithms underestimate the risk of cardiovascular disease in schizophrenia: Evidence from a national primary care database. Schizophrenia Research 159: 176-181.
27. Maguire GA, (2002) Prolactin elevation with antipsychotic medication: Mechanism of action and clinical consequences. Journal of Clinical Psychiatry 63: 56-62.
28. Majeed A, (2014) Statins for primary prevention of cardiovascular disease. British Medical Journal 348: g3491.
29. Marder SR, Essock SM, Miller AL, et al. (2004) Physical health monitoring of patients with schizophrenia. American Journal of Psychiatry 161: 1334-1349.
30. Mercer SW, Tessier S, (2001) A qualitative study of general practitioners' and practice nurses' attitudes to obesity management in primary care. Health Bulletin (Edinburgh) 59: 248-253.
31. Mitchell AJ, Hardy SA, (2013) Screening for metabolic risk among patients with severe mental illness and diabetes: A national comparison. Psychiatric Services 64: 1060-1063.
32. Mitchell AJ, Vancampfort D, De Herdt A, et al. (2013) Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients. Schizophrenia Bulletin 39: 295-305.
33. Morrato EH, Newcomer JW, Kamat S, et al. (2009) Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes. Diabetes Care 32: 1037-1042.
34. National Heart, Lung and Blood Institute (2014) US National Institutes of Health. Risk Assessment Tool for Estimating Your 10-year Risk of Having a Heart Attack (Framingham Risk Score).,. Available at: http://cvdrisk.nhlbi.nih.gov (. accessed 30 August 2015).
35. National Institute for Health and Care Excellence (NICE) (2014) NICE Guideline CG178: Psychosis and schizophrenia in adults: Treatment and management.,. Available at: www.nice.org.uk/guidance/CG178/chapter/introduction (. accessed 30 August 2015).
36. Newcomer JW, (2005) Second-generation (atypical) antipsychotics and metabolic effects: A comprehensive literature review. CNS Drugs 19: 1-93.
37. Osborn DP, (2014) Predicting and preventing cardiovascular disease in people with severe mental illnesses. Results from the PRIMROSE study in UK primary care. Presented at the International Congress of the Royal College of Psychiatrists (Psychiatry: The Heartland of Medicine), Barbican Centre, London, 24 June.
38. Osborn DP, Hardoon S, Omar RZ, et al. (2015) Cardiovascular risk prediction models for people with severe mental illness: Results from the prediction and management of cardiovascular risk in people with severe mental illnesses (PRIMROSE) research program. JAMA Psychiatry 72: 143-151.
39. Osborn DP, Levy G, Nazareth I, et al. (2007) Relative risk of cardiovascular and cancer mortality in people with severe enduring mental illness from the United Kingdom's General Practice Research database. Archives in General Psychiatry 64: 242-249.
40. Smith M, Hopkins D, Peveler RC, et al. (2008) First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: Systematic review and meta-analysis. British Journal of Psychiatry 192: 406-411.
41. Townsend P, (1987) Deprivation. Journal of Social Policy 16: 125-146.